Sunday 18 October 2026
Export PALI’s income statement to Excel — free account
Palisade Bio, Inc.
PALI Healthcare Biotechnology
Palisade Bio, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $250,000.00. In the quarter to June 2026, revenue grew 19,900.0%, EPS grew 91.4% and free cash flow fell 318.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
1.41
0.13
−8.44%
Follow PALI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(228.73%) | (24.52%) | (36.40%) | (51.37%) | |
| (137.67%) | (23.11%) | (34.13%) | (47.68%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(335.10%) | (12.95%) | (18.92%) | (26.18%) | |
Average Days of Receivables |
— | — | — | 241.72 | |
Free Cash Flow per Share |
(1.35) | (0.19) | (0.06) | (0.09) | |
Free Cash Flow |
(10.08) | (10.85) | (12.40) | (18.19) | |
| Other line items | |||||
Cash ROIC |
(116.58%) | (4.12%) | (4.77%) | (7.37%) | |
Accounts Receivable Turnover |
— | — | — | 0.78 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 2,829.67% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 1,918.54% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 1,708.48% | |
Interest Coverage |
(1,041.55) | (1,805.60) | (2,649.40) | — | |
Operating CF/Net income |
0.90 | 0.65 | 0.51 | 0.57 | |
Depreciation/Fixed assets |
0.00 | 0.00 | — | — | |
Capex/Depreciation |
0.00 | 0.00 | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.35) | (0.19) | (0.06) | (0.09) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates